

[Home](#)[2. FDA PI](#)[3. Mebaral](#)

## Mebaral: Package Insert / Prescribing Info

### Package insert / product label

**Generic name:** mephobarbital

**Dosage form:** tablet

**Drug classes:** [Barbiturate anticonvulsants](#), [Barbiturates](#)

[Medically reviewed](#) by Drugs.com. Last updated on Mar 24, 2025.


### On This Page

[Description](#)[Clinical Pharmacology](#)[Indications and Usage](#)[Contraindications](#)[Warnings](#)[Precautions](#)[Patient Counseling Information](#)[Drug Interactions](#)[Adverse Reactions/Side Effects](#)[Drug Abuse and Dependence](#)[Overdosage](#)[Dosage and Administration](#)[How Supplied/Storage and Handling](#)

## Mebaral Description

Mephobarbital, 5-Ethyl-1-methyl-5-phenylbarbituric acid, is a barbiturate with sedative, hypnotic, and anticonvulsant properties. It occurs as a white, nearly odorless, tasteless powder and is slightly soluble in water and in alcohol.

MEBARAL is available as tablets for oral administration. The structural formula is:



Inactive Ingredients: Lactose, Starch, Stearic Acid, Talc.

# Mebaral - Clinical Pharmacology

Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia.

Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis.

Barbiturates are respiratory depressants. The degree of respiratory depression is dependent upon dose. With hypnotic doses, respiratory depression produced by barbiturates is similar to that which occurs during physiologic sleep with slight decrease in blood pressure and heart rate.

Studies in laboratory animals have shown that barbiturates cause reduction in the tone and contractility of the uterus, ureters, and urinary bladder. However, concentrations of the drugs required to produce this effect in humans are not reached with sedative-hypnotic doses.

Barbiturates do not impair normal hepatic function, but have been shown to induce liver microsomal enzymes, thus increasing and/or altering the metabolism of barbiturates and other drugs. (See [PRECAUTIONS-Drug Interactions](#).)

MEBARAL exerts a strong sedative and anticonvulsant action but has a relatively mild hypnotic effect. It reduces the incidence of epileptic seizures in grand mal and petit mal. MEBARAL usually causes little or no drowsiness or lassitude. Hence, when it is used as a sedative or anticonvulsant, patients usually become more calm, more cheerful, and better adjusted to their surroundings without clouding of mental faculties. MEBARAL is reported to produce less sedation than does phenobarbital.

Barbiturates are weak acids that are absorbed and rapidly distributed to all tissues and fluids with high concentrations in the brain, liver, and kidneys. Lipid solubility of the barbiturates is the dominant factor in their distribution within the body. Barbiturates are bound to plasma and tissue proteins to a varying degree with the degree of binding increasing directly as a function of lipid solubility.

Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract. Therapeutic plasma concentrations for mephobarbital have not been established nor has the half-life been determined. Following oral administration, the onset of action of the drug is 30 to 60 minutes and the duration of action is 10 to 16 hours. The primary route of mephobarbital metabolism is N-demethylation by the microsomal enzymes of the liver to form phenobarbital. Phenobarbital may be excreted in the urine unchanged or further metabolized to p-hydroxyphenobarbital and excreted in the urine as glucuronide or sulfate conjugates. About 75% of a single oral dose of mephobarbital is converted to phenobarbital in 24 hours.

Therefore, chronic administration of mephobarbital may lead to an accumulation of phenobarbital (not mephobarbital) in plasma. It has not been determined whether mephobarbital or phenobarbital is the active agent during long-time mephobarbital therapy.

## Indications and Usage for Mebaral

MEBARAL is indicated for use as a sedative for the relief of anxiety, tension, and apprehension, and as an anticonvulsant for the treatment of grand mal and petit mal epilepsy.

## Contraindications

Hypersensitivity to any barbiturate. Manifest or latent porphyria.

# Warnings

## Habit Forming

Barbiturates may be habit forming. Tolerance, psychological, and physical dependence may occur with continued use. (See [DRUG ABUSE AND DEPENDENCE](#) and [CLINICAL PHARMACOLOGY](#).) Patients who have psychological dependence on barbiturates may increase the dosage or decrease the dosage interval without consulting a physician and may subsequently develop a physical dependence on barbiturates. To minimize the possibility of overdosage or the development of dependence, the prescribing and dispensing of sedative-hypnotic barbiturates should be limited to the amount required for the interval until the next appointment. Abrupt cessation after prolonged use in the dependent person may result in withdrawal symptoms, including delirium, convulsions, and possibly death. Barbiturates should be withdrawn gradually from any patient known to be taking excessive dosage over long periods of time. (See [DRUG ABUSE AND DEPENDENCE](#).)

## Acute or Chronic Pain

Caution should be exercised when barbiturates are administered to patients with acute or chronic pain, because paradoxical excitement could be induced or important symptoms could be masked. However, the use of barbiturates as sedatives in the postoperative surgical period and as adjuncts to cancer chemotherapy is well established.

## Use in Pregnancy

Barbiturates can cause fetal damage when administered to a pregnant woman. Retrospective, case-controlled studies have suggested a connection between the maternal consumption of barbiturates and a higher than expected incidence of fetal abnormalities. Following oral or parenteral administration, barbiturates readily cross the placental barrier and are distributed throughout fetal tissues with highest concentrations found in the placenta, fetal liver, and brain. Fetal blood levels approach maternal blood levels following parenteral administration.

Withdrawal symptoms occur in infants born to mothers who receive barbiturates throughout the last trimester of pregnancy. (See [DRUG ABUSE AND DEPENDENCE](#).) If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

## Synergistic Effects

The concomitant use of alcohol or other CNS depressants may produce additive CNS depressant effects.

## Precautions

### General

Barbiturates may be habit forming. Tolerance and psychological and physical dependence may occur with continuing use. (See [DRUG ABUSE AND DEPENDENCE](#).) Barbiturates should be administered with caution, if at all, to patients who are mentally depressed, have suicidal tendencies, or a history of drug abuse.

Elderly or debilitated patients may react to barbiturates with marked excitement, depression, and confusion. In some persons, barbiturates repeatedly produce excitement rather than depression.

In patients with hepatic damage, barbiturates should be administered with caution and initially in reduced doses. Barbiturates should not be administered to patients showing the premonitory signs of hepatic coma.

Status epilepticus may result from the abrupt discontinuation of MEBARAL, even when administered in small daily doses in the treatment of epilepsy.

Caution and careful adjustment of dosage are required when MEBARAL is used in patients with impaired renal, cardiac or respiratory function, and in patients with myasthenia gravis and myxedema. The least quantity feasible should be prescribed or dispensed at any one time in order to minimize the possibility of acute or chronic overdosage.

**Vitamin D Deficiency:** MEBARAL may increase vitamin D requirements, possibly by increasing vitamin D metabolism via enzyme induction. Rarely, rickets and osteomalacia have been reported following prolonged use of barbiturates.

**Vitamin K:** Bleeding in the early neonatal period due to coagulation defects may follow exposure to anticonvulsant drugs in utero; therefore, vitamin K should be given to the mother before delivery or to the child at birth.

## Information for the Patient

Practitioners should give the following information and instructions to patients receiving barbiturates.

1. The use of barbiturates carries with it an associated risk of psychological and/or physical dependence. The patient should be warned against increasing the dose of the drug without consulting a physician.
2. Barbiturates may impair mental and/or physical abilities required for the performance of potentially hazardous tasks (e.g., driving, operating machinery, etc.).
3. Alcohol should not be consumed while taking barbiturates. Concurrent use of the barbiturates with other CNS depressants (e.g., alcohol, narcotics, tranquilizers, and antihistamines) may result in additional CNS depressant effects.

## Laboratory Tests

Prolonged therapy with barbiturates should be accompanied by periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic systems. (See [PRECAUTIONS \[General\]](#) and [ADVERSE REACTIONS](#).)

## Drug Interactions

Most reports of clinically significant drug interactions occurring with the barbiturates have involved phenobarbital. However, the application of these data to other barbiturates appears valid and warrants serial blood level determinations of the relevant drugs when there are multiple therapies.

1. Anticoagulants. Phenobarbital lowers the plasma levels of dicumarol (name previously used: bishydroxycoumarin) and causes a decrease in anticoagulant activity as measured by the prothrombin time. Barbiturates can induce hepatic microsomal enzymes resulting in increased metabolism and decreased anticoagulant response of oral anticoagulants (e.g., warfarin, acenocoumarol, dicumarol, and phenprocoumon). Patients stabilized on anticoagulant therapy may require dosage adjustments if barbiturates are added to or withdrawn from their dosage regimen.
2. Corticosteroids. Barbiturates appear to enhance the metabolism of exogenous corticosteroids probably through the induction of hepatic microsomal enzymes. Patients stabilized on corticosteroid therapy may require dosage adjustments if barbiturates are added to or withdrawn from their dosage regimen.
3. Griseofulvin. Phenobarbital appears to interfere with the absorption of orally administered griseofulvin, thus decreasing its blood level. The effect of the resultant decreased blood levels of griseofulvin on therapeutic response has not been established. However, it would be preferable to avoid concomitant administration of these drugs.
4. Doxycycline. Phenobarbital has been shown to shorten the half-life of doxycycline for as long as 2 weeks after

barbiturate therapy is discontinued.

This mechanism is probably through the induction of hepatic microsomal enzymes that metabolize the antibiotic. If phenobarbital and doxycycline are administered concurrently, the clinical response to doxycycline should be monitored closely.

5. Phenytoin, Sodium Valproate, Valproic Acid. The effect of barbiturates on the metabolism of phenytoin appears to be variable. Some investigators report an accelerating effect, while others report no effect. Because the effect of barbiturates on the metabolism of phenytoin is not predictable, phenytoin and barbiturate blood levels should be monitored more frequently if these drugs are given concurrently. Sodium valproate and valproic acid appear to decrease barbiturate metabolism; therefore, barbiturate blood levels should be monitored and appropriate dosage adjustments made as indicated.

6. Central Nervous System Depressants. The concomitant use of other central nervous system depressants, including other sedatives or hypnotics, antihistamines, tranquilizers, or alcohol, may produce additive depressant effects.

7. Monoamine Oxidase Inhibitors (MAOI). MAOI prolong the effects of barbiturates probably because metabolism of the barbiturate is inhibited.

8. Estradiol, Estrone, Progesterone, and other Steroidal Hormones. Pretreatment with or concurrent administration of phenobarbital may decrease the effect of estradiol by increasing its metabolism. There have been reports of patients treated with antiepileptic drugs (e.g., phenobarbital) who become pregnant while taking oral contraceptives. An alternate contraceptive method might be suggested to women taking phenobarbital.

## Carcinogenesis

Animal Data. Phenobarbital sodium is carcinogenic in mice and rats after lifetime administration. In mice, it produced benign and malignant liver cell tumors. In rats, benign liver cell tumors were observed very late in life. Phenobarbital is the major metabolite of MEBARAL.

Human Data. In a 29-year epidemiological study of 9,136 patients who were treated on an anticonvulsant protocol which included phenobarbital, results indicated a higher than normal incidence of hepatic carcinoma. Previously, some of these patients were treated with thorotrast, a drug which is known to produce hepatic carcinomas. Thus, this study did not provide sufficient evidence that phenobarbital sodium is carcinogenic in humans. Phenobarbital is the major metabolite of MEBARAL.

A retrospective study of 84 children with brain tumors matched to 73 normal controls and 78 cancer controls (malignant disease other than brain tumors) suggested an association between exposure to barbiturates prenatally and an increased incidence of brain tumors.

## Pregnancy

Teratogenic Effects. Pregnancy Category D - See [WARNINGS-Use in Pregnancy](#).

Nonteratogenic Effects. Reports of infants suffering from long-term barbiturate exposure in utero included the acute withdrawal syndrome of seizures and hyperirritability from birth to a delayed onset of up to 14 days. (See [DRUG ABUSE AND DEPENDENCE](#).)

## Labor and Delivery

Hypnotic doses of these barbiturates do not appear to significantly impair uterine activity during labor. Full anesthetic

doses of barbiturates decrease the force and frequency of uterine contractions. Administration of sedative-hypnotic barbiturates to the mother during labor may result in respiratory depression in the newborn. Premature infants are particularly susceptible to the depressant effects of barbiturates. If barbiturates are used during labor and delivery, resuscitation equipment should be available.

Data are currently not available to evaluate the effect of these barbiturates when forceps delivery or other intervention is necessary. Also, data are not available to determine the effect of these barbiturates on the later growth, development, and functional maturation of the child.

## **Nursing Mothers**

Caution should be exercised when a barbiturate is administered to a nursing woman since small amounts of barbiturates are excreted in the milk.

## **Adverse Reactions/Side Effects**

The following adverse reactions and their incidence were compiled from surveillance of thousands of hospitalized patients. Because such patients may be less aware of certain of the milder adverse effects of barbiturates, the incidence of these reactions may be somewhat higher in fully ambulatory patients.

More than 1 in 100 Patients. The most common adverse reactions estimated to occur at a rate of 1 to 3 patients per 100 is:

Nervous System: Somnolence.

Less than 1 in 100 Patients. Adverse reactions estimated to occur at a rate of less than 1 in 100 patients listed below, grouped by organ system, and by decreasing order of occurrence are:

Nervous System: Agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality.

Respiratory System: Hypoventilation, apnea.

Cardiovascular System: Bradycardia, hypotension, syncope.

Digestive System: Nausea, vomiting, constipation.

Other Reported Reactions: Headache, hypersensitivity reactions (angioedema, skin rashes, exfoliative dermatitis), fever, liver damage, megaloblastic anemia following chronic phenobarbital use.

**To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck Inc. at 1-800-455-1141 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## **Drug Abuse and Dependence**

Mephobarbital is a controlled substance in Narcotic Schedule IV. Barbiturates may be habit forming. Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an intoxicating dosage and fatal dosage becomes smaller.

Symptoms of acute intoxication with barbiturates include unsteady gait, slurred speech, and sustained nystagmus. Mental signs of chronic intoxication include confusion, poor judgment, irritability, insomnia, and somatic complaints.

Symptoms of barbiturate dependence are similar to those of chronic alcoholism. If an individual appears to be intoxicated with alcohol to a degree that is radically disproportionate to the amount of alcohol in his or her blood the use of barbiturates should be suspected. The lethal dose of a barbiturate is far less if alcohol is also ingested.

The symptoms of barbiturate withdrawal can be severe and may cause death. Minor withdrawal symptoms may appear 8 to 12 hours after the last dose of a barbiturate. These symptoms usually appear in the following order: anxiety, muscle twitching, tremor of hands and fingers, progressive weakness, dizziness, distortion in visual perception, nausea, vomiting, insomnia, and orthostatic hypotension. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Individuals susceptible to a barbiturate abuse and dependence include alcoholics and opiate abusers, as well as other sedative-hypnotic and amphetamine abusers.

Drug dependence to barbiturates arises from repeated administration of a barbiturate or agent with barbiturate-like effect on a continuous basis, generally in amounts exceeding therapeutic dose levels. The characteristics of drug dependence to barbiturates include: (a) a strong desire or need to continue taking the drug; (b) a tendency to increase the dose; (c) a psychic dependence on the effects of the drug related to subjective and individual appreciation of those effects; and (d) a physical dependence on the effects of the drug requiring its presence for maintenance of homeostasis and resulting in a definite, characteristic, and self-limited abstinence syndrome when the drug is withdrawn.

Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. In all cases withdrawal takes an extended period of time. One method involves substituting a 30 mg dose of phenobarbital for each 100 mg to 200 mg dose of barbiturate that the patient has been taking. The total daily amount of phenobarbital is then administered in 3 to 4 divided doses, not to exceed 600 mg daily. Should signs of withdrawal occur on the first day of treatment, a loading dose of 100 mg to 200 mg of phenobarbital may be administered IM in addition to the oral dose. After stabilization on phenobarbital, the total daily dose is decreased by 30 mg a day as long as withdrawal is proceeding smoothly. A modification of this regimen involves initiating treatment at the patient's regular dosage level and decreasing the daily dosage by 10% if tolerated by the patient.

Infants physically dependent on barbiturates may be given phenobarbital 3 mg/kg/day to 10 mg/kg/day. After withdrawal symptoms (hyperactivity, disturbed sleep, tremors, hyperreflexia) are relieved, the dosage of phenobarbital should be gradually decreased and completely withdrawn over a 2-week period.

## Overdosage

The toxic dose of barbiturates varies considerably. In general, an oral dose of 1 g of most barbiturates produces serious poisoning in an adult. Death commonly occurs after 2 g to 10 g of ingested barbiturate. Barbiturate intoxication may be confused with alcoholism, bromide intoxication, and with various neurological disorders.

Acute overdosage with barbiturates is manifested by CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may show paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.

In extreme overdose, all electrical activity in the brain may cease, in which case a "flat" EEG normally equated with clinical death cannot be accepted. This effect is fully reversible unless hypoxic damage occurs. Consideration should be given to the possibility of barbiturate intoxication even in situations that appear to involve trauma.

Complications such as pneumonia, pulmonary edema, cardiac arrhythmias, congestive heart failure, and renal failure may occur. Uremia may increase CNS sensitivity to barbiturates if renal function is impaired. Differential diagnosis should include hypoglycemia, head trauma, cerebrovascular accidents, convulsive states, and diabetic coma.

Treatment of overdose is mainly supportive and consists of the following:

1. Maintenance of an adequate airway, with assisted respiration and oxygen administration as necessary.
2. Monitoring of vital signs and fluid balance.
3. If the patient is conscious and has not lost the gag reflex, emesis may be induced with ipecac. Care should be taken to prevent pulmonary aspiration of vomitus. After completion of vomiting, 30 g activated charcoal in a glass of water may be administered.
4. If emesis is contraindicated, gastric lavage may be performed with a cuffed endotracheal tube in place with the patient in the face down position. Activated charcoal may be left in the emptied stomach and a saline cathartic administered.
5. Fluid therapy and other standard treatment for shock, if needed.
6. If renal function is normal, forced diuresis may aid in the elimination of the barbiturate. Alkalinization of the urine increases renal excretion of some barbiturates, including mephobarbital (which is metabolized to phenobarbital).
7. Although not recommended as a routine procedure, hemodialysis may be used in severe barbiturate intoxications or if the patient is anuric or in shock.
8. Patient should be rolled from side to side every 30 minutes.
9. Antibiotics should be given if pneumonia is suspected.
10. Appropriate nursing care to prevent hypostatic pneumonia, decubiti aspiration, and other complications of patients with altered states of consciousness.

## **Mebaral Dosage and Administration**

### **Epilepsy**

Average dose for adults: 400 mg to 600 mg (6 grains to 9 grains) daily; children under 5 years: 16 mg to 32 mg (1/4 grain to 1/2 grain) three or four times daily; children over 5 years: 32 mg to 64 mg (1/2 grain to 1 grain) three or four times daily. MEBARAL is best taken at bedtime if seizures generally occur at night, and during the day if attacks are diurnal.

Treatment should be started with a small dose which is gradually increased over four or five days until the optimum dosage is determined. If the patient has been taking some other antiepileptic drug, it should be tapered off as the doses of MEBARAL are increased, to guard against the temporary marked attacks that may occur when any treatment for epilepsy is changed abruptly. Similarly, when the dose is lowered to a maintenance level or to be discontinued, the amount should be reduced gradually over four or five days.

### **Special Patient Population**

Dosage should be reduced in the elderly or debilitated because these patients may be more sensitive to barbiturates. Dosage should be reduced for patients with impaired renal function or hepatic disease.



## Combination with Other Drugs

MEBARAL may be used in combination with phenobarbital, either in the form of alternating courses or concurrently. When the two drugs are used at the same time, the dose should be about one-half the amount of each used alone. The average daily dose for an adult is from 50 mg to 100 mg (3/4 grain to 1 1/2 grains) of phenobarbital and from 200 mg to 300 mg (3 grains to 4 1/2 grains) of MEBARAL.

MEBARAL may also be used with phenytoin sodium; in some cases, combined therapy appears to give better results than either agent used alone, since phenytoin sodium is particularly effective for the psychomotor types of seizure but relatively ineffective for petit mal. When the drugs are employed concurrently, a reduced dose of phenytoin sodium is advisable, but the full dose of MEBARAL may be given. Satisfactory results have been obtained with an average daily dose of 230 mg (3 1/2 grains) of phenytoin sodium plus about 600 mg (9 grains) of MEBARAL.

## Sedation

Adults: 32 mg to 100 mg (1/2 grain to 1 1/2 grains)-optimum dose, 50 mg (3/4 grain)-three to four times daily. Children: 16 mg to 32 mg (1/4 grain to 1/2 grain) three to four times daily.

## How is Mebaral supplied

Tablets - white, round, convex and the 32 mg tablets are scored.

32 mg (1/2 grain), bottles of 250  
(NDC 67386-801-02).

50 mg (3/4 grain), bottles of 250  
(NDC 67386-802-02).

100 mg (1 1/2 grains), bottles of 250  
(NDC 67386-803-02).

Store at room temperature up to 25°C (77°F).

Manufactured by:  
Bayer HealthCare LLC  
Myerstown, PA 17067, U.S.A.

For: Lundbeck Inc.  
Deerfield, IL 60015, U.S.A.

® Trademark of Lundbeck Inc.

Revised: May 2009


## PRINCIPAL DISPLAY PANEL



NDC 67386-801-02 (32 mg, 1/2 grain)

Bottle:

NDC 67386-801-02 250 Tablets

**Mebaral<sup>®</sup>**  
(mephobarbital tablets, USP)

**32 mg** (1/2 grain) 

R<sub>x</sub> only  

Exp Lot


Lundbeck Inc.  
Deerfield, IL 60015, U.S.A.



Usual sedative dose:  
1 to 3 tablets three to four times daily.  
See package insert for full prescribing information.  
Store at room temperature up to 77°F (25°C).  
Dispense in tight, light-resistant container as defined in the official compendia.  
Manufactured by: Bayer HealthCare LLC  
Myerstown, PA 17067, U.S.A.  
For: Lundbeck Inc.  
Deerfield, IL 60015, U.S.A.  
82119184

Package:

NDC 67386-801-02 12 x 250 Tablets

**Mebaral<sup>®</sup>**  
(mephobarbital tablets, USP)

**32 mg** (1/2 grain) 

R<sub>x</sub> only  

Exp Lot

Manufactured by: Bayer HealthCare LLC  
For: Lundbeck Inc., Deerfield, IL 60015, U.S.A.


Store at room temperature up to 77°F (25°C).  
82119192



NDC 67386-802-02 (50 mg, 3/4 grain)

Bottle:

NDC 67386-802-02 250 Tablets

**Mebaral<sup>®</sup>**  
(mephobarbital tablets, USP)

**50 mg** (3/4 grain) 

R<sub>x</sub> only  

Exp Lot

Lundbeck Inc.  
Deerfield, IL 60015, U.S.A.


Usual sedative dose: 1 to 2 tablets three to four times daily.  
See package insert for full prescribing information.  
Store at room temperature up to 77°F (25°C).  
Dispense in tight, light-resistant container as defined in the official compendia.  
Manufactured by: Bayer HealthCare LLC  
Myerstown, PA 17067, U.S.A.  
For: Lundbeck Inc.  
Deerfield, IL 60015, U.S.A.  
82119206

Package:



NDC 67386-802-02 12 x 250 Tablets

Exp  
Lot

**Mebaral<sup>®</sup>**  
(mephobarbital tablets, USP)

**50 mg** 

(3/4 grain)

**Rx only**

Manufactured by: Bayer HealthCare LLC  
For: Lundbeck Inc., Deerfield, IL 60015, U.S.A.

67386-802-02

Store at room temperature up to 77°F (25°C).  
82119222


NDC 67386-803-02 (100 mg, 1 1/2 grain)

Bottle:



NDC 67386-803-02 250 Tablets

Exp  
Lot

**Mebaral<sup>®</sup>**  
(mephobarbital tablets, USP)

**100 mg** 

(1 1/2 grains)

**Rx only**

Manufactured by:  
Bayer HealthCare LLC  
Myerstown, PA 17067, U.S.A.  
For: Lundbeck Inc.  
Deerfield, IL 60015, U.S.A.  
82088831

Usual sedative dose:  
1/2 to 1 tablet three to four times daily.  
See package insert for full prescribing information.  
Store at room temperature up to 77°F (25°C).  
Dispense in tight, light-resistant container as defined in the official compendia.

67386-803-02

MEBARAL

mephobarbital tablet

Product Information

|                         |                         |                    |               |
|-------------------------|-------------------------|--------------------|---------------|
| Product Type            | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:67386-801 |
| Route of Administration | ORAL                    | DEA Schedule       | CIV           |

Active Ingredient/Active Moiety

|  |                   |          |
|--|-------------------|----------|
| Ingredient Name  | Basis of Strength | Strength |
| MEPHOBARBITAL (UNII: 5NC67NU76B) (MEPHOBARBITAL - UNII:5NC67NU76B) | MEPHOBARBITAL     | 32 mg    |

Inactive Ingredients

|                                 |          |
|---------------------------------|----------|
| Ingredient Name                 | Strength |
| LACTOSE (UNII: J2B2A4N98G)      |          |
| STARCH, CORN (UNII: O8232NY3SJ) |          |
| STEARIC ACID (UNII: 4ELV7Z65AP) |          |
| TALC (UNII: 7SEV7J4R1U)         |          |

Product Characteristics

|        |               |              |          |
|--------|---------------|--------------|----------|
| Color  | white (white) | Score        | 2 pieces |
| Shape  | ROUND (ROUND) | Size         | 6mm      |
| Flavor |               | Imprint Code | M;31     |

Contains

Packaging

| # | Item Code        | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---------------------|----------------------|--------------------|
| 1 | NDC:67386-801-02 | 72 in 1 CASE        |                      |                    |
| 1 |                  | 250 in 1 BOTTLE     |                      |                    |

Marketing Information

|                       |  |                      |                    |
|-----------------------|--|----------------------|--------------------|
| Marketing Category    | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other |  | 01/15/1935           |                    |

MEBARAL

mephobarbital tablet

Product Information

|                         |                         |                    |               |
|-------------------------|-------------------------|--------------------|---------------|
| Product Type            | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:67386-802 |
| Route of Administration | ORAL                    | DEA Schedule       | CIV           |

Active Ingredient/Active Moiety

|  |                   |          |
|--|-------------------|----------|
| Ingredient Name  | Basis of Strength | Strength |
| MEPHOBARBITAL (UNII: 5NC67NU76B) (MEPHOBARBITAL - UNII:5NC67NU76B) | MEPHOBARBITAL     | 50 mg    |

Inactive Ingredients

|                                 |          |
|---------------------------------|----------|
| Ingredient Name                 | Strength |
| LACTOSE (UNII: J2B2A4N98G)      |          |
| STARCH, CORN (UNII: O8232NY3SJ) |          |
| STEARIC ACID (UNII: 4ELV7Z65AP) |          |
| TALC (UNII: 7SEV7J4R1U)         |          |

Product Characteristics

|        |               |              |          |
|--------|---------------|--------------|----------|
| Color  | white (white) | Score        | no score |
| Shape  | ROUND (ROUND) | Size         | 8mm      |
| Flavor |               | Imprint Code | M;32     |

Contains

Packaging

| # | Item Code        | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---------------------|----------------------|--------------------|
| 1 | NDC:67386-802-02 | 72 in 1 CASE        |                      |                    |
| 1 |                  | 250 in 1 BOTTLE     |                      |                    |

Marketing Information

|                       |  |                      |                    |
|-----------------------|--|----------------------|--------------------|
| Marketing Category    | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other |  | 01/15/1935           |                    |

MEBARAL

mephobarbital tablet

Product Information

|                         |                         |                    |               |
|-------------------------|-------------------------|--------------------|---------------|
| Product Type            | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:67386-803 |
| Route of Administration | ORAL                    | DEA Schedule       | CIV           |

Active Ingredient/Active Moiety

|  |                   |          |
|--|-------------------|----------|
| Ingredient Name  | Basis of Strength | Strength |
| MEPHOBARBITAL (UNII: 5NC67NU76B) (MEPHOBARBITAL - UNII:5NC67NU76B) | MEPHOBARBITAL     | 100 mg   |

Inactive Ingredients

|                                 |          |
|---------------------------------|----------|
| Ingredient Name                 | Strength |
| LACTOSE (UNII: J2B2A4N98G)      |          |
| STARCH, CORN (UNII: O8232NY3SJ) |          |
| STEARIC ACID (UNII: 4ELV7Z65AP) |          |
| TALC (UNII: 7SEV7J4R1U)         |          |

Product Characteristics

|        |               |              |          |
|--------|---------------|--------------|----------|
| Color  | white (white) | Score        | no score |
| Shape  | ROUND (ROUND) | Size         | 10mm     |
| Flavor |               | Imprint Code | M;33     |

Contains

Packaging

| # | Item Code        | Package Description | Marketing Start Date | Marketing End Date |
|---|------------------|---------------------|----------------------|--------------------|
| 1 | NDC:67386-803-02 | 12 in 1 CASE        |                      |                    |
| 1 |                  | 250 in 1 BOTTLE     |                      |                    |

Marketing Information

|                       |  |                      |                    |
|-----------------------|--|----------------------|--------------------|
| Marketing Category    | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| Unapproved drug other |  | 01/15/1935           |                    |

Labeler - Lundbeck Inc. (018343595)

Establishment

|                      |         |           |                     |
|----------------------|---------|-----------|---------------------|
| Name                 | Address | ID/FEI    | Business Operations |
| Bayer HealthCare LLC |         | 072827066 | MANUFACTURE         |

# More about Mebaral (mephobarbital)

- [Check interactions](#)
- [Compare alternatives](#)
- [Reviews \(4\)](#)
- [Drug images](#)
- [Side effects](#)
- [Dosage information](#)
- [During pregnancy](#)
- [Drug class: barbiturate anticonvulsants](#)

## Professional resources



- [Mephobarbital prescribing information](#)

## Related treatment guides

- [Sedation](#)
- [Seizure Prevention](#)
- [Epilepsy](#)

[Medical Disclaimer](#)

### DRUG STATUS

|   |                          |
|---|--------------------------|
| <b>Availability</b>   |                          |
|  | Discontinued             |
| <b>Pregnancy &amp; Lactation</b>  |                          |
|  | Risk data available      |
| <b>CSA Schedule*</b>  |                          |
| 4   | Some potential for abuse |



## User Reviews & Ratings

[4 Reviews](#)

## Images

[Mebaral 32 mg \(M 31\)](#)



[View larger images](#)

# Drugs.com Mobile App

Access drug & treatment information, identify pills, check interactions and set up personal medication records.



## About

[About Drugs.com](#)

[Advertising policy](#)

[Attribution & citations](#)

## Terms & privacy

[Terms of use](#)

[Editorial policy](#)

[Privacy policy](#)

## Support

[Help center](#)

[Sitemap](#)

[Contact us](#)



[Subscribe to our newsletter](#) for the latest medication news, new drug approvals and FDA alerts.

**Drugs.com** provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 7 Apr 2025), Cerner Multum™ (updated 13 Apr 2025), ASHP (updated 10 Apr 2025) and others.



Ad Choices  
ADVERTISEMENT



Copyright © 2000-2025 Drugs.com. All rights reserved.